Media coverage about Flexion Therapeutics (NASDAQ:FLXN) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.6060096945679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Flexion Therapeutics (FLXN) Reports Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA … – StreetInsider.com (streetinsider.com)
- Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) (finance.yahoo.com)
- 3 Biotechs Launching Their First Commercial Drugs in 2018 (finance.yahoo.com)
- Zacks: Brokerages Anticipate Flexion Therapeutics Inc (FLXN) Will Announce Quarterly Sales of $1.29 Million (americanbankingnews.com)
Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at $25.79 on Thursday. The firm has a market capitalization of $968.18, a P/E ratio of -7.33 and a beta of 1.14. Flexion Therapeutics has a 52 week low of $16.51 and a 52 week high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93.
Several brokerages have issued reports on FLXN. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Needham & Company LLC upped their target price on Flexion Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 target price on shares of Flexion Therapeutics in a research note on Friday, November 10th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $37.00 target price (up previously from $35.00) on shares of Flexion Therapeutics in a research note on Monday, October 9th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $106.25.
In related news, insider Michael D. Clayman acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was purchased at an average price of $23.60 per share, with a total value of $118,000.00. Following the completion of the purchase, the insider now owns 35,395 shares in the company, valued at approximately $835,322. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Neil Bodick acquired 2,700 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were bought at an average cost of $24.49 per share, with a total value of $66,123.00. Following the purchase, the insider now owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The disclosure for this purchase can be found here. Corporate insiders own 15.98% of the company’s stock.
WARNING: This piece of content was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/11/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-flexion-therapeutics-flxn-stock-price.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.